You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: 7,744,886


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,744,886
Title:Methods for interfering with rank signaling
Abstract: Disclosed herein are methods for interfering with RANK signaling by administering blocking antibodies that bind a RANKL polypeptide and inhibit the binding of the RANKL polypeptide to a RANK polypeptide.
Inventor(s): Anderson; Dirk M (Port Townsend, WA)
Assignee: Immunex Corporation (Thousand Oaks, CA)
Application Number:12/214,914
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 7,744,886

Introduction

When analyzing a specific patent, such as United States Patent 7,744,886, it is crucial to delve into the claims, the broader patent landscape, and the legal and regulatory context that governs patent law. This analysis will help in understanding the patent's validity, its position within the industry, and potential legal implications.

Understanding the Patent Claims

To begin with, it is essential to carefully examine the claims of the patent. Patent claims define the scope of the invention and are critical in determining what is protected under the patent.

Claim Construction

Claim construction involves interpreting the language of the claims to understand their scope. This process is often a point of contention in patent litigation, as the interpretation can significantly impact the patent's validity and enforceability[5].

Types of Claims

Patents typically include various types of claims, such as independent claims, dependent claims, and method claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims. Method claims describe the steps involved in the invention.

The Broader Patent Landscape

The patent landscape includes all patents related to the same or similar technologies. Analyzing this landscape helps in understanding the competitive environment and potential risks.

Patent Filings and Trends

The number and distribution of patent filings in a particular field can indicate the level of innovation and competition. For instance, in emerging fields like quantum computing, the patent landscape is rapidly evolving, with key players and countries dominating the filings[3].

Geographic and Socioeconomic Disparities

Patenting activity is not evenly distributed across the United States. Certain regions, such as the coasts and parts of Texas, show higher patenting intensity. This disparity can have economic implications and may necessitate policy changes to promote innovation in under-resourced areas[4].

Legal and Regulatory Context

The legal and regulatory framework governing patents is crucial for understanding the validity and enforceability of a patent.

Inventorship and AI-Assisted Inventions

Recent guidance from the USPTO clarifies that AI systems cannot be named as inventors on patents. Instead, human beings must make significant contributions to the invention for it to be patentable. This guidance emphasizes the importance of human ingenuity in the patent process[1].

Obviousness-Type Double Patenting

The Federal Circuit has ruled that patent owners must disclaim any term in subsequent patent applications that would extend the term of already-issued patents. This doctrine prevents the granting of multiple patents on the same invention, ensuring that inventors do not unfairly extend the term of their patents[2].

Litigation and Disputes

Patent litigation often arises from disputes over inventorship, claim construction, and the validity of patents.

Significant Contribution and Litigation

Determining whether a human being has made a significant contribution to an AI-assisted invention can be complex and may lead to litigation. Attorneys must gather evidence, such as the prompts used with AI systems, to support the inventorship claims[1].

Terminal Disclaimers and Patent Term Adjustments

The Federal Circuit's decision in In re Cellect highlights the importance of filing terminal disclaimers to avoid issues with obviousness-type double patenting. Failure to do so can result in the invalidation of patents due to unjustified extensions of term[2].

Patent Analysis Tools

Using objective patent analysis tools can help in reviewing patent applications before submission to the USPTO. These tools can identify potential issues such as procedural objections, Section 112 rejections, and post-grant challenges, thereby reducing patent prosecution delays and costs[5].

Diversity in Patenting

The patent landscape also reflects broader societal issues, such as gender and racial disparities in patenting activity. Addressing these disparities through policy changes, such as collecting demographic data and providing additional guidance to pro se applicants, can help in promoting a more diverse innovation ecosystem[4].

Policy Implications

Policy changes can significantly impact the patent landscape. For example, the CHIPS and Science Act aims to create regional innovation hubs to spur development in under-resourced regions. Congress may also consider reforms to the patent examination process to increase diversity among inventors[4].

Key Takeaways

  • Patent Claims: Carefully constructed claims are essential for defining the scope of the invention and determining what is protected under the patent.
  • Patent Landscape: Understanding the broader patent landscape helps in identifying trends, competition, and potential risks.
  • Inventorship: Human beings must make significant contributions to AI-assisted inventions for them to be patentable.
  • Litigation: Disputes over inventorship, claim construction, and patent term adjustments can lead to complex litigation.
  • Diversity: Addressing disparities in patenting activity can promote a more diverse and inclusive innovation ecosystem.
  • Policy: Policy changes can impact the patent landscape, encouraging innovation and addressing inequities.

FAQs

  1. Can AI systems be named as inventors on patents? No, according to the USPTO guidance, AI systems cannot be named as inventors on patents. Only human beings who make significant contributions to the invention can be named as inventors[1].

  2. What is obviousness-type double patenting? Obviousness-type double patenting is a doctrine that prevents the granting of multiple patents on the same invention or obvious modifications thereof. It requires patent owners to disclaim any term in subsequent patent applications that would extend the term of already-issued patents[2].

  3. How can patent analysis tools help in the patent application process? Patent analysis tools can help identify potential issues such as procedural objections, Section 112 rejections, and post-grant challenges, thereby reducing patent prosecution delays and costs[5].

  4. What are the implications of geographic disparities in patenting activity? Geographic disparities in patenting activity can have economic implications and may necessitate policy changes to promote innovation in under-resourced areas. Addressing these disparities can drive economic growth and higher living standards more uniformly across the country[4].

  5. How can policy changes address diversity in patenting? Policy changes, such as collecting demographic data and providing additional guidance to pro se applicants, can help in promoting a more diverse innovation ecosystem. Initiatives like the CHIPS and Science Act aim to create regional innovation hubs to spur development in under-resourced regions[4].

Sources

  1. U.S. Patent and Trademark Office Issues Guidance on Inventorship for AI-Assisted Inventions - Fredrikson & Byron P.A.
  2. Federal Circuit Puts the Onus on Patent Owners to Disclaim Patent - Mintz
  3. Quantum Leap: Decoding Quantum Computing Innovation - Stanford Center for Responsible Quantum Technology
  4. Equity in Innovation: Trends in U.S. Patenting and Inventor Diversity - Congressional Research Service
  5. Patent Analysis Tools for Objective Application Review - LexisNexis IP

More… ↓

⤷  Subscribe

Details for Patent 7,744,886

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. PROLIA denosumab Injection 125320 June 01, 2010 ⤷  Subscribe 2016-12-23
Amgen Inc. XGEVA denosumab Injection 125320 November 18, 2010 ⤷  Subscribe 2016-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 7,744,886

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9958674 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 9828426 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 9828424 ⤷  Subscribe
United States of America 8715683 ⤷  Subscribe
United States of America 8569456 ⤷  Subscribe
United States of America 8377690 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.